Equities

Genomtec SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Genomtec SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)4.58
  • Today's Change-0.22 / -4.58%
  • Shares traded18.23k
  • 1 Year change-36.48%
  • Beta0.0087
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genomtec SA is a Poland-based company engaged in biotechnology and medical research business sector and it is operating in the field of clinical diagnostics. The Company is focused on development of of Genomtec ID, a mobile platform for genetic diagnosis in the point of patient care. Its creation and commercialization allows the diagnostic process to be executed in point of care setting, such as: primary care clinics, pharmacies, doctor’s offices, hospital emergency departments (ERs) without the need for complicated and time-consuming laboratory workflow conducted by qualified personnel.

  • Revenue in PLN (TTM)15.00k
  • Net income in PLN-11.01m
  • Incorporated2017
  • Employees--
  • Location
    Genomtec SAWroclawski Park Biznesu 3ul. Bierutowska 57-59WROCLAW 51-317PolandPOL
  • Websitehttps://genomtec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stem Cells Spin SA115.74k-510.92k16.53m1.00--2.5312.67142.86-0.0124-0.01240.00280.15810.01030.0083.43115,740.00-4.52-1.02-4.57-1.0595.9193.18-441.44-50.721.03-133.660.0262---87.06-37.78-237.07------
Medicofarma Biotech SA281.45k-3.06m35.48m24.00--7.46--126.08-0.0450-0.04500.00410.070.019966.640.746911,727.08-21.55-14.96-31.48-18.5938.8036.02-1,085.51-64.020.821-11.710.00--63.14-17.3933.11------
GENOMED SA27.49m3.27m37.79m53.0011.553.049.371.372.482.4820.819.422.215.1712.68509,166.1026.317.5128.798.8165.2462.3311.903.847.51--0.00--2.343.1819.321.9815.97--
Sds Optic SA7.44m-483.71k50.40m41.00--51.32228.836.77-0.0815-0.08151.250.15590.54975.12125.84181,486.60-4.01-32.89-4.24-41.3598.1949.49-7.29-136.622.500.62780.00--40.53301.05-45.06--57.27--
Sygnis SA7.73m-6.34m56.50m12.00--1.76--7.31-0.2499-0.24990.33091.170.1166-0.16896.14218,427.70-9.03-8.61-15.00-12.10108.4959.85-77.44-39.140.6697-0.00660.13---52.2926.88-47.44---9.50--
Read Gene SA15.19m-887.46k71.21m11.00--26.58--4.69-0.0536-0.05361.170.22731.0839.776.30---6.32-2.40-6.88-2.7492.6390.21-5.84-4.306.31-0.6960.00--30.3826.3817.49------
Genomtec SA15.00k-11.01m72.31m----6.99--4,820.68-0.7485-0.74850.0010.68690.0009--0.0143---65.47-89.96-82.11-113.38-54,120.00-4,379.72-73,393.34-17,225.072.82-39.820.1409--0.00-63.42-24.35---34.54--
Hyenergy SA3.29m169.85k77.91m27.00--3.95318.9023.69-0.0936-0.09360.16540.58780.18210.12590.7741--0.94032.391.283.3599.7077.465.163.111.301.170.00--192.8319.47100.30---45.79--
Nanogroup SA-6.90k-6.93m83.88m----7.19-----0.1844-0.1844-0.00020.3553-0.00032.64-----30.59-29.50-51.55-33.80--66.72---2,258.260.9785-464.180.00--3.96-64.0934.50--3.07--
Urteste SA0.00-5.47m87.29m34.00--3.73-----3.88-3.880.0015.350.00-------15.56-29.65-18.99-31.35---45,933.33---623,333.30----0.0128------35.00--197.79--
Poltreg SA0.00-24.56m122.65m33.00--2.48-----5.27-5.270.0010.610.0016.45--0.00-25.87-9.02-29.62-10.18---659.36---854.232.65--0.1365---74.98-6.89-38.06--83.47--
Mabion SA14.81m-59.30m132.37m204.00--1.89--8.94-3.67-3.670.91644.330.09888.1027.2572,602.94-39.560.5366-54.811.06-178.5558.34-400.370.96430.2276--0.04---54.50---115.35--6.00--
Molecure SA5.11m-24.42m140.93m71.00--1.58--27.57-1.20-1.200.24934.340.0553--7.0150,119.41-26.42-3.15-27.53-3.3051.4893.34-477.67-15.45----0.0588---40.47278.20-10.27--12.49--
Data as of Feb 06 2026. Currency figures normalised to Genomtec SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.